Literature DB >> 14983223

Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.

Jolanta Małyszko1, Jacek S Małyszko, Tomasz Hryszko, Michał Myśliwiec.   

Abstract

Patients dialyzed due to diabetic nephropathy are at a higher risk of death due to cardiovascular complications than dialyzed non-diabetic patients. Disturbances in hemostasis may play a role in the vascular complications of diabetes mellitus. It has been postulated that TAFI-thrombin activatable fibrinolysis inhibitor, which couples two opposite systems: coagulation and fibrinolysis, may be involved in the mechanism of vascular endothelial damage in diabetic patients. We assessed: TAFI and TAFIa, markers of ongoing coagulation: thrombin-antithrombin complexes, prothrombin fragments 1+2, a marker of ongoing fibrinolysis: plasmin-antiplasmin complexes in diabetic and non-diabetic patients on hemodialyses-HD, peritoneal dialyses-CAPD, patients with chronic renal failure with and without diabetic nephropathy on conservative treatment. Both groups of dialyzed diabetic patients have a higher concentration of markers of ongoing coagulation and TAFI activity when compared to dialyzed non-diabetic patients. Linear regression analysis showed that TAFI concentration was directly related to albumin in HD and CAPD patients without diabetic nephropathy, whereas TAFIa correlated with triglycerides, fibrinogen and leukocytes count in this group. When evaluated separately (HD, CAPD), significant correlations between TAFIa and triglycerides and fibrinogen were found only in diabetic CAPD patients. Multivariate analysis showed no correlation between TAFI and other parameters studied. In conclusion, elevated circulating TAFI and TAFIa might be a new link in the pathogenesis of impaired fibrinolysis in diabetic nephropathy, and thus atherosclerosis progression, particularly in CAPD patients. Hypercoagulable state observed in diabetic patients on conservative treatment and maintained on dialyses may contribute to the higher cardiovascular mortality in this population. In these patients there is also evidence of endothelial injury, and probably secondary activation of the coagulation cascade.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14983223     DOI: 10.1160/TH03-04-0243

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia.

Authors:  Gulay S Guven; Enver Atalar; Bunyamin Yavuz; Yavuz Beyazit; Murat Kekilli; Alparslan Kilicarslan; Levent Sahiner; Gul Oz; Necla Ozer; Serdar Aksoyek; Ibrahim C Haznedaroglu; Tumay Sozen
Journal:  J Natl Med Assoc       Date:  2006-04       Impact factor: 1.798

2.  Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.

Authors:  M Erdogan; S Solmaz; A Canataroglu; M Kulaksızoglu; S Cetinkalp; A G Ozgen; F Saygili; C Yilmaz
Journal:  Endocrine       Date:  2010-04-14       Impact factor: 3.633

Review 3.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

4.  Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts.

Authors:  Chih-Cheng Wu; Mu-Yang Hsieh; Szu-Chun Hung; Ko-Lin Kuo; Tung-Hu Tsai; Chao-Lun Lai; Jaw-Wen Chen; Shing-Jong Lin; Po-Hsun Huang; Der-Cherng Tarng
Journal:  J Am Soc Nephrol       Date:  2015-10-09       Impact factor: 10.121

Review 5.  Impact of Indoxyl Sulfate on Progenitor Cell-Related Neovascularization of Peripheral Arterial Disease and Post-Angioplasty Thrombosis of Dialysis Vascular Access.

Authors:  Chih-Cheng Wu; Szu-Chun Hung; Ko-Lin Kuo; Der-Cherng Tarng
Journal:  Toxins (Basel)       Date:  2017-01-07       Impact factor: 4.546

6.  Effects of blood glucose and glycosylated hemoglobin levels on intravenous thrombolysis in patients with acute cerebral infarction and type 2 diabetes mellitus.

Authors:  Zhaoting Zhang; Mingyue Qian; Zhonglin Ge; Ping Zhou; Jianhua Liu; Jiechun Chen
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.